

**Anti-IL-13 Reference Antibody (tralokinumab)  
Recombinant Antibody  
Catalog # APR10222****Specification**

---

**Anti-IL-13 Reference Antibody (tralokinumab) - Product Information**

|                   |                        |
|-------------------|------------------------|
| Application       | FC, E, FTA             |
| Primary Accession | <a href="#">P35225</a> |
| Reactivity        | Human, Mouse           |
| Clonality         | Monoclonal             |
| Isotype           | IgG4SP                 |
| Calculated MW     | 144.14 KDa             |

**Anti-IL-13 Reference Antibody (tralokinumab) - Additional Information****Target/Specificity**

IL-13

**Endotoxin**

&lt; 0.001EU/ µg,determined by LAL method.

**Conjugation**

Unconjugated

**Expression system**

CHO Cell

**Format**

Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

**Anti-IL-13 Reference Antibody (tralokinumab) - Protein Information****Name** IL13**Synonyms** NC30**Function**

Cytokine that plays important roles in allergic inflammation and immune response to parasite infection (PubMed:<a href="http://www.uniprot.org/citations/8096327" target="\_blank">8096327</a>, PubMed:<a href="http://www.uniprot.org/citations/8097324" target="\_blank">8097324</a>). Synergizes with IL2 in regulating interferon-gamma synthesis (PubMed:<a href="http://www.uniprot.org/citations/8096327" target="\_blank">8096327</a>). Stimulates B-cell proliferation, and activation of eosinophils, basophils, and mast cells (PubMed:<a href="http://www.uniprot.org/citations/7903680" target="\_blank">7903680</a>, PubMed:<a href="http://www.uniprot.org/citations/8759755" target="\_blank">8759755</a>). Plays an important role in controlling IL33 activity by modulating the production of transmembrane and soluble forms of interleukin-1 receptor-like 1/IL1RL1 (By similarity). Displays the capacity to

antagonize Th1-driven proinflammatory immune response and downregulates synthesis of many proinflammatory cytokines including IL1, IL6, IL10, IL12 and TNF-alpha through a mechanism that partially involves suppression of NF-kappa-B (By similarity). Functions also on nonhematopoietic cells, including endothelial cells where it induces vascular cell adhesion protein 1/VCAM1, which is important in the recruitment of eosinophils (PubMed:<a href="http://www.uniprot.org/citations/8639787" target="\_blank">8639787</a>). Exerts its biological effects through its receptors which comprises the IL4R chain and the IL13RA1 chain, to activate JAK1 and TYK2, leading to the activation of STAT6 (PubMed:<a href="http://www.uniprot.org/citations/9013879" target="\_blank">9013879</a>). Aside from IL13RA1, another receptor IL13RA2 acts as a high affinity decoy for IL13 and mediates internalization and depletion of extracellular IL13 (PubMed:<a href="http://www.uniprot.org/citations/21622864" target="\_blank">21622864</a>).

### Cellular Location


Secreted.

### Anti-IL-13 Reference Antibody (tralokinumab) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

### Anti-IL-13 Reference Antibody (tralokinumab) - Images



Anti-IL-13 Reference Antibody (tralokinumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-IL-13 Reference Antibody (tralokinumab) is more than 100% ,determined by SEC-HPLC.